Scarica l'app Stockscreener
5.66
0.88%
-0.05
Dopo l'orario di chiusura:
5.66
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché FOLD Giù?
Forum
Previsione
Precedente Chiudi:
$5.71
Aprire:
$5.7
Volume 24 ore:
2.70M
Relative Volume:
0.61
Capitalizzazione di mercato:
$1.88B
Reddito:
$493.67M
Utile/perdita netta:
$-104.69M
Rapporto P/E:
-16.65
EPS:
-0.34
Flusso di cassa netto:
$-31.51M
1 W Prestazione:
-1.22%
1M Prestazione:
-9.00%
6M Prestazione:
-42.19%
1 anno Prestazione:
-42.65%
Intervallo 1D:
$5.51
$5.73
Intervallo di 1 settimana:
$5.51
$5.8199
Portata 52W:
$5.51
$12.65
Amicus Therapeutics Inc Stock (FOLD) Company Profile
Nome
Amicus Therapeutics Inc
Settore
Industria
Telefono
(609) 662-2000
Indirizzo
47 HULFISH STREET, PRINCETON, NJ
Confronta FOLD con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
FOLD
Amicus Therapeutics Inc
|
5.66 | 1.88B | 493.67M | -104.69M | -31.51M | -0.34 |
|
VRTX
Vertex Pharmaceuticals Inc
|
445.82 | 115.95B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
520.29 | 56.52B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
321.82 | 39.44B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
560.53 | 35.14B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
267.12 | 28.51B | 3.81B | -644.79M | -669.77M | -6.24 |
Amicus Therapeutics Inc Stock (FOLD) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2024-12-13 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2024-09-06 | Iniziato | Jefferies | Buy |
| 2024-05-30 | Iniziato | Wells Fargo | Overweight |
| 2024-05-14 | Aggiornamento | Guggenheim | Neutral → Buy |
| 2023-12-19 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2022-09-09 | Iniziato | Morgan Stanley | Equal-Weight |
| 2022-04-13 | Ripresa | Goldman | Neutral |
| 2022-01-14 | Aggiornamento | SVB Leerink | Mkt Perform → Outperform |
| 2021-11-15 | Aggiornamento | Stifel | Hold → Buy |
| 2021-09-30 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2021-07-19 | Ripresa | BTIG Research | Buy |
| 2021-05-27 | Iniziato | Needham | Hold |
| 2021-05-21 | Iniziato | UBS | Buy |
| 2021-04-14 | Aggiornamento | Cantor Fitzgerald | Neutral → Overweight |
| 2021-03-02 | Iniziato | Stifel | Hold |
| 2021-02-12 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| 2021-02-12 | Downgrade | JP Morgan | Overweight → Neutral |
| 2020-12-28 | Ripresa | Cantor Fitzgerald | Overweight |
| 2020-12-10 | Downgrade | Citigroup | Buy → Neutral |
| 2020-11-11 | Iniziato | Berenberg | Hold |
| 2020-06-17 | Iniziato | BTIG Research | Buy |
| 2020-02-04 | Ripresa | Cantor Fitzgerald | Overweight |
| 2019-11-12 | Reiterato | H.C. Wainwright | Buy |
| 2019-06-17 | Iniziato | H.C. Wainwright | Buy |
| 2019-06-05 | Reiterato | Cantor Fitzgerald | Overweight |
| 2019-04-05 | Iniziato | Janney | Buy |
| 2019-01-30 | Iniziato | Cantor Fitzgerald | Overweight |
| 2018-10-29 | Iniziato | Citigroup | Neutral |
| 2018-08-17 | Downgrade | Chardan Capital Markets | Buy → Neutral |
| 2017-10-06 | Ripresa | Goldman | Neutral |
| 2017-09-13 | Reiterato | Chardan Capital Markets | Buy |
| 2017-08-10 | Reiterato | Chardan Capital Markets | Buy |
| 2017-01-24 | Aggiornamento | Robert W. Baird | Neutral → Outperform |
| 2016-05-18 | Iniziato | BofA/Merrill | Buy |
| 2016-04-14 | Iniziato | Robert W. Baird | Neutral |
| 2016-04-12 | Reiterato | Chardan Capital Markets | Buy |
| 2015-09-16 | Downgrade | Chardan Capital Markets | Buy → Neutral |
| 2015-06-16 | Reiterato | Chardan Capital Markets | Buy |
Mostra tutto
Amicus Therapeutics Inc Borsa (FOLD) Ultime notizie
When Will Amicus Therapeutics, Inc. (NASDAQ:FOLD) Turn A Profit? - simplywall.st
Amicus Therapeutics (NASDAQ:FOLD) Hits New 52-Week LowTime to Sell? - MarketBeat
Amicus Therapeutics stock hits 52-week low at 5.79 USD By Investing.com - Investing.com Canada
Amicus Therapeutics, Inc. (NASDAQ:FOLD) Receives $16.22 Average Price Target from Analysts - MarketBeat
(FOLD) Technical Data - news.stocktradersdaily.com
Amicus Therapeutics, Inc. (NASDAQ:FOLD) Shares Sold by Wedge Capital Management L L P NC - MarketBeat
Amicus Therapeutics: Opportunity Awaits In This Beaten Down Pharma (NASDAQ:FOLD) - Seeking Alpha
Amicus Therapeutics at Goldman Sachs Conference: Strategic Insights Unveiled By Investing.com - Investing.com Canada
Fabry Disease Market to Grow Rapidly During the Study Period (2020–2034) | DelveInsight - Yahoo Finance
Zacks Research Issues Pessimistic Outlook for FOLD Earnings - MarketBeat
Two Sigma Investments LP Increases Stock Position in Amicus Therapeutics, Inc. (NASDAQ:FOLD) - MarketBeat
Pompe Disease Therapeutic Market Deep Research Report with - openPR.com
Millennium Management LLC Buys 44,449 Shares of Amicus Therapeutics, Inc. (NASDAQ:FOLD) - MarketBeat
UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Boosts Holdings in Amicus Therapeutics, Inc. (NASDAQ:FOLD) - MarketBeat
New Analysis of Pombiliti® (cipaglucosidase alfa-atga) + Opfolda - GuruFocus
New Strong Sell Stocks for June 3rd - Yahoo Finance
Amicus (FOLD) Reports Positive Findings from PROPEL Study in Pompe Disease | FOLD Stock News - GuruFocus
New Analysis of Pombiliti® (cipaglucosidase alfa-atga) + Opfolda® (miglustat) Published in Muscle and Nerve - GlobeNewswire
Clinical Data Reveals Treatment Advantages: 77% of Pompe Disease Patients Show Improvement with New Therapy - Stock Titan
Two Sigma Advisers LP Acquires 52,000 Shares of Amicus Therapeutics, Inc. (NASDAQ:FOLD) - MarketBeat
Cetera Investment Advisers Takes Position in Amicus Therapeutics, Inc. (NASDAQ:FOLD) - Defense World
How to Take Advantage of moves in (FOLD) - news.stocktradersdaily.com
Man Group plc Decreases Stake in Amicus Therapeutics, Inc. (NASDAQ:FOLD) - MarketBeat
Amicus Therapeutics to Present at Upcoming Investor Conferences in June 2025 - GlobeNewswire
Amicus Therapeutics to Present at Upcoming Investor Conferences in June 2025 | FOLD Stock News - GuruFocus
Rare Disease Leader Amicus Therapeutics to Present Latest Updates at Major Healthcare Conferences - Stock Titan
Millennium Management LLC Has $4.31 Million Holdings in Amicus Therapeutics, Inc. (NASDAQ:FOLD) - Defense World
Voloridge Investment Management LLC Sells 397,497 Shares of Amicus Therapeutics, Inc. (NASDAQ:FOLD) - MarketBeat
Squarepoint Ops LLC Purchases 753,060 Shares of Amicus Therapeutics, Inc. (NASDAQ:FOLD) - MarketBeat
Neo Ivy Capital Management Increases Stock Position in Amicus Therapeutics, Inc. (NASDAQ:FOLD) - MarketBeat
Woodline Partners LP Sells 726,952 Shares of Amicus Therapeutics, Inc. (NASDAQ:FOLD) - MarketBeat
Amicus Therapeutics, Inc. (NASDAQ:FOLD) Shares Purchased by Ameriprise Financial Inc. - Defense World
Pompe Disease Market: Epidemiology, Therapies, Companies, - openPR.com
Teza Capital Management LLC Sells 68,066 Shares of Amicus Therapeutics, Inc. (NASDAQ:FOLD) - MarketBeat
Nuveen Asset Management LLC Purchases 159,139 Shares of Amicus Therapeutics, Inc. (NASDAQ:FOLD) - MarketBeat
Amicus Therapeutics, Inc. (NASDAQ:FOLD) Receives Consensus Recommendation of "Moderate Buy" from Analysts - MarketBeat
297,830 Shares in Amicus Therapeutics, Inc. (NASDAQ:FOLD) Bought by Sovereign s Capital Management LLC - MarketBeat
Vestal Point Capital LP Acquires New Holdings in Amicus Therapeutics, Inc. (NASDAQ:FOLD) - MarketBeat
Deutsche Bank AG Grows Position in Amicus Therapeutics, Inc. (NASDAQ:FOLD) - MarketBeat
Rafferty Asset Management LLC Sells 73,883 Shares of Amicus Therapeutics, Inc. (NASDAQ:FOLD) - MarketBeat
Amicus Therapeutics Inc Azioni (FOLD) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Amicus Therapeutics Inc Azioni (FOLD) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Campbell Bradley L | President and CEO |
Feb 19 '25 |
Sale |
10.00 |
400 |
4,000 |
1,150,657 |
0.92%
0.01%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):